Brooklyn Investment Group Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Brooklyn Investment Group grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,131 shares of the medical equipment provider’s stock after purchasing an additional 145 shares during the quarter. Brooklyn Investment Group’s holdings in Hologic were worth $82,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. FMR LLC lifted its holdings in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the period. Mackenzie Financial Corp raised its stake in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after buying an additional 544,889 shares during the last quarter. Marshall Wace LLP bought a new position in Hologic during the second quarter valued at about $39,427,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Hologic by 21.6% during the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after buying an additional 450,190 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 0.3 %

Shares of NASDAQ:HOLX opened at $69.73 on Monday. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock’s 50-day moving average price is $74.84 and its 200-day moving average price is $78.41. The stock has a market capitalization of $15.82 billion, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.89 EPS. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HOLX. Jefferies Financial Group began coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Monday, January 13th. UBS Group boosted their target price on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Evercore ISI increased their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. boosted their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $88.92.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.75% of the stock is currently owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.